Shared on 02 Nov 25
Fair value Increased 19%Analysts have raised their price target for Xeris Biopharma Holdings from $9.00 to $10.67, citing updated fair value assessments and recalibrated forecasts for the company’s financial outlook. What's in the News Xeris Biopharma Holdings raised its full-year 2025 total revenue guidance to $280 to $290 million, up from the prior range of $260 to $275 million (Key Developments).
Shared on 23 Aug 25
Fair value Increased 10%Driven by improvements in net profit margin and revenue growth forecasts, analysts have raised their fair value estimate for Xeris Biopharma Holdings from $8.17 to $9.00. What's in the News Xeris Biopharma Holdings raised full-year 2025 revenue guidance to $280–$290 million, up from the prior range of $260–$275 million.
Shared on 08 Aug 25
Fair value Increased 30%The significant upward revision in Xeris Biopharma Holdings’ price target reflects rising future P/E expectations despite a decline in net profit margin, resulting in a fair value increase from $6.30 to $7.80. What's in the News Xeris Biopharma Holdings raised full-year 2025 total revenue guidance to $280-$290 million from $260-$275 million.